R1 RCM Inc (RCM) EPS Estimated At $-0.03

October 13, 2017 - By Henry Gaston

 R1 RCM Inc (RCM) EPS Estimated At $ 0.03

Analysts expect R1 RCM Inc (NASDAQ:RCM) to report $-0.03 EPS on November, 1.They anticipate $0.21 EPS change or 116.67 % from last quarter’s $0.18 EPS. After having $-0.11 EPS previously, R1 RCM Inc’s analysts see -72.73 % EPS growth. The stock increased 1.15% or $0.04 during the last trading session, reaching $3.53. About 385,969 shares traded or 61.97% up from the average. R1 RCM Inc (NASDAQ:RCM) has 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

R1 RCM Inc., formerly Accretive Health, Inc., is a well-known provider of revenue cycle management and physician advisory services (PAS) to healthcare providers. The company has market cap of $366.07 million. The Firm is engaged in providing management services of revenue cycle activities for the United States hospitals and other medical services providers. It currently has negative earnings. The Company’s primary service offering consists of end-to-end RCM, which the Company deploys through a co-managed relationship or an operating partner relationship.

More notable recent R1 RCM Inc (NASDAQ:RCM) news were published by: Globenewswire.com which released: “R1 RCM Reports Fourth Quarter and Full Year 2016 Results” on March 01, 2017, also Seekingalpha.com with their article: “R1 RCM’s (ACHI) CEO Joe Flanagan on Q4 2016 Results – Earnings Call Transcript” published on March 02, 2017, Seekingalpha.com published: “R1 RCM’s (RCM) CEO Joseph Flanagan on Q1 2017 Results – Earnings Call Transcript” on May 10, 2017. More interesting news about R1 RCM Inc (NASDAQ:RCM) were released by: Chicagobusiness.com and their article: “After years of turmoil, Accretive Health ditches name” published on January 06, 2017 as well as Seekingalpha.com‘s news article titled: “R1 RCM’s (RCM) CEO Joseph Flanagan on Q2 2017 Results – Earnings Call Transcript” with publication date: August 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.